Skip to content
  • English
  • Business
  • Entertainment
  • National
  • Lifestyle
  • Education
Daily News India

Daily News India

Just another WordPress site

  • English
  • Business
  • Entertainment
  • National
  • Lifestyle
  • Education
  • Toggle search form
  • Keeping Ayurveda alive, Sona Healthcare is a one-stop solution to all your healthcare needs Business
  • Fredna Vet Diagnostics Hosts CE Programme on Exotic Animal Medicine Business
  • InvestX Charts Striking Success with 200 Crores in Inaugural Year Business
  • ETS India Strengthens South Asia Leadership to Drive TOEFL and GRE Growth Business
  • Celebrating the Teachings of Shri Guru Nanak Dev Ji: A Message of Giving, Equality, and Selflessness- Dr Vivek Bindra National
  • JustJob Launches “Post Your Jobs” Campaign, Offering Employers Access to a Diverse Database of 25 Lakhs Candidates Across Geographies Business
  • Wockhardt observes The World Diabetes Day, continuing to serve diabetic patients with quality medicines at affordable prices Business
  • NSDC and Amity University Online collaborate to skill young learners professionally Press Release

ISSAR Pharma Announces Out-Licensing of Its Peptide-Based NCEs

Posted on April 29, 2021 By

ISSAR Pharma, the only company in India which focuses on the research and development of New Chemical Entities (NCE), is licensing out its NCEs based on peptide technology, opening opportunities for fruitful partnerships.

Hyderabad (Telangana) [India], April 29: ISSAR Pharmaceuticals, the Pioneer in Peptide Technology and peptide drug innovation, has decided to license out their peptide-based New Chemical Entities (NCEs), with pre-IND filing and US Patent. The potential collaboration would help ISSAR Pharmaceuticals in their goal to design and deliver novel peptide-based drugs for various unmet healthcare needs of the population and making them affordable and accessible for better health outcomes.

ISSAR Pharmaceuticals exclusively focuses on peptide technology-based research and development of New Chemical Entities (NCE) for various unmet medical needs to improve the quality of life. ISSAR uses Solid-phase peptide synthesis as the technology of choice and has the capability to synthesize custom peptides, API peptides, and cosmetic peptides at all scales within a short duration. With an emphasis on quality, safety, and innovation, ISSAR has demonstrated the ability to move products from conceptualisation to commercialisation of peptide molecules at all stages. ISSAR has several patents for potential life-changing peptide molecules lined up in their development pipeline targeting therapeutic areas such as oncology, dermatology, gastroenterology, and diseases of bones and joints.

“We take pride in being India’s first-ever company to conduct phase-1 clinical trials and launch the first-ever indigenous peptide drug, Melgain in the market for the treatment of Vitiligo in 2004”, informs Mr. Ramakrishna Reddy Isanaka, the founder of ISSAR. ISSAR’s

FDA- compliant state-of-the-art manufacturing facility of 62000 sq. ft., is purely into peptide manufacturing technology, located in Genome Valley, Hyderabad, India. In addition to its experience in R&D, ISSAR is equipped with the most advanced and automatic technology with expertise in the synthesis and purification of peptides, producing the highest standards of purity of up to 99.5% by continued process optimization.

With over 25 years of experience and a prime focus in Research and Development, ISSAR’s dedicated team of experts is proud to have developed India’s first-ever peptide molecule, Melgain for the treatment of Vitiligo in 2004, which is now introduced as Novoskin® with improved properties and effectiveness. ISSAR’s commitment has also led to the development of their second New Chemical Entity called Xylentra, which is the first-ever peptide drug in the world for the treatment of burn wounds and microbial infections.

ISSAR developed molecules for prevalent conditions in the Western world such as Inflammatory Bowel Diseases (IBD), Psoriasis, and Sepsis. Recently, an NCE for the treatment of burn wounds (Xylentra) was licensed to Viatris, formerly known as Mylan Laboratories, the USA in 2020.

ISSAR Pharmaceuticals was founded by Mr. Ramakrishna Reddy Isanaka in 1995 with a vision to be a global leader in peptide drug discovery for improving patients’ quality of life. Before starting ISSAR Pharmaceutical, Mr.Isanaka was the promoter and director of Shantha Biotechnics in the 1980s, at a time when Biotechnology was new to India.

His efforts in research and development led to the advancement of ISSAR Pharma as the first-ever company in India to conduct Phase-I Clinical Trials in the year 1995. Today, he has over 25 years of experience in the development of NCEs with 2 successfully commercialized products, 7 plus patents to his credit, and over 6 commercially viable products under development.

https://issar.co.in/

English, Health, Press Release Tags:ISSARPharma, PeptidebasedNCEs, PNN

Post navigation

Previous Post: Glimpse up the world @worldwithmaria
Next Post: Indian Furniture Rental Industry – Market Size, Growth & Scope

Related Posts

  • Non-Surgical, Next Generation Cryoablation Technology- A Boon for Cancer Patients Health
  • The Revolutionary AI Health Monitoring Tool Every Indian Should Know About Health
  • Kingston HyperX Sets DDR4 Overclocking World Record at 7156MHz English
  • Munish Forge Limited IPO Opens on Sept 30, 2025 Press Release
  • Leading the Future of Cardiac Care: Dr. Brajmohan Singh’s Journey in Advanced Heart Surgery Health
  • FORE School of Management completes final placements for 2020-22 batch, highest package at 41 LPA Press Release

Recent Posts

  • Ye Mahaveer Ka Panth Hai, Har Prani Me Sant Hai’ – Mahavir Nirvana Katha resonates at Bharat Mandapam
  • Unihealth Hospitals Limited Reports H1 FY27 Revenue of Rs 76.45 Crore; Positive Operating Cash Flow of Rs 23.83 Crore Amidst Significant Expansion Investments
  • Chhattisgarh CM Inaugurates PanIIT Alumni India’s Nursing Skill College Initiative in Jashpur
  • 8th International HKL Conference Begins at Gurdwara Bulandpuri Sahib; Flags of 116 Nations Hoisted to Promote Global Unity
  • Cash Ur Drive Marketing Reports Strong H1 FY27 Performance: EBITDA Rising 13% and Net Profit Growing 8% YoY

Recent Comments

  • Unknown on Participants Reap Rewards in Wellman’s 8-Week Digital Campaign: IPL Tickets, Autographed Virat Kohli Merchandise, and More!
  • Integrated Industries Ltd Announces New Product Launch by Subsidiary Nurture Well Foods Private Limited Lifestyle
  • My Interior Designers Brings Clarity to Bangalore’s Interior Search Journey Business
  • India’s Changing Movie Audience: What Viewers Want Today Entertainment
  • Where the Hotel Lobby Becomes a Classroom  Business
  • A New Era of AI Begins in Astrology: Future Point and AIFAS Launch Advanced AI Astrology Software Business
  • Indian AI startup Blinkit-AI Secures USD 1.2 Million in Funding to Scale Unified AI Services in India Press Release
  • Vivek Sethia All Set to Revolutionize How Sports are perceived in India with his new venture “Breaking Sports with Vivek Sethia” Business
  • RACE Eco Chain’s UDAAN witnessed the participation of waste dealers from across 28 states of India Press Release

Copyright © 2026 Daily News India.

Powered by PressBook News WordPress theme